CURRENT STATUS
For the first time in decades, psychiatry has genuinely new mechanisms. Cobenfy (KarXT) treats schizophrenia through muscarinic receptors β no direct dopamine blockade. Rapid-acting agents (esketamine, zuranolone) work in days, not weeks. Accelerated neurostimulation (SAINT) and carefully studied psychedelics are reshaping treatment-resistant depression and PTSD.
KEY BREAKTHROUGHS
Cobenfy (xanomelineβtrospium, KarXT) β first non-dopaminergic antipsychotic for schizophrenia in decades, FDA-approved 2024
Zuranolone (Zurzuvae) β first oral rapid-acting treatment for postpartum depression, works within days
Esketamine (Spravato) β approved as monotherapy for treatment-resistant depression, targeting the glutamate system
SAINT accelerated TMS β fMRI-guided neurostimulation achieving rapid remission in treatment-resistant depression
AI-COMPRESSED PIPELINE
AI TOOLS ACCELERATING CURES
KEY ORGANIZATIONS
KEY CLINICAL TRIALS
XanomelineβTrospium (KarXT / Cobenfy) Expansion Trials
ViewBristol Myers Squibb (Karuna)
Building on the EMERGENT schizophrenia program, trials are testing the muscarinic agonist combination for Alzheimer's-related psychosis and as adjunctive therapy β a mechanism that avoids the metabolic and movement side effects of dopamine blockers.
Psilocybin for Treatment-Resistant Depression (Phase 3)
ViewCompass Pathways / academic
Rigorous, psychologically-supported trials of a single or repeated dose of psilocybin for major depression that has not responded to standard antidepressants, with careful screening and structured therapy.
TIMELINE ESTIMATE
New-mechanism antipsychotic & rapid antidepressants: available now. Psychedelic-assisted therapy (broad approval): 2β5 years. Biomarker-guided precision psychiatry: 5β10 years.